표준 치료를 받고 있는 제2형 당뇨병 환자에서 오령산 병용 투여의 후향적 약물 상호작용 연구
A Retrospective Herb-Drug Interaction Study of Oryeong-san (Wuling-san) Co-administration in Type 2 Diabetes Patients Receiving Hypoglycemic Treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study investigated the effects of Korean medicine Oryeong-san (五苓散) on blood glucose levels and evaluated its safety in patients with type 2 diabetes. Methods: A total of 87 patients aged 19 years and older, hospitalized for at least three days at the Kyung Hee University Korean Medical Hospital from January 1, 2021, to December 31, 2023 and continuously consumed Oryeong-san for a minimum of three days, were included. Their clinical characteristics and laboratory tests were reviewed retrospectively. The effects of Oryeong-san on fasting (FBS) and 2-hour postprandial (PP2) blood glucose were assessed by comparing the averages of measurements taken before and after the treatment. To evaluate the safety of the herbal extract, liver function test and kidney function test results were compared, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (Cr), and estimated glomerular filtration rate (eGFR). Results: The average duration of Oryeong-san consumption was 17.71±26.82 days. Although the FBS decreased and the PP2 slightly increased, these changes were not statistically significant (p>0.05). Safety assessments showed that the average levels of AST decreased, while the level of ALT increased, without statistical significance. The BUN levels also significantly decreased, while Cr and eGFR levels remained stable. Conclusion: This study indicates that Oryeong-san is safe for use in type 2 diabetes patients without significant impact on blood glucose and that it has a positive safety profile.
Abstract
Objectives: This study investigated the effects of Korean medicine Oryeong-san (五苓散) on blood glucose levels and evaluated its safety in patients with type 2 diabetes. Methods: A total of 87 patients aged 19 years and older, hospitalized for at least three days at the Kyung Hee University Korean Medical Hospital from January 1, 2021, to December 31, 2023 and continuously consumed Oryeong-san for a minimum of three days, were included. Their clinical characteristics and laboratory tests were reviewed retrospectively. The effects of Oryeong-san on fasting (FBS) and 2-hour postprandial (PP2) blood glucose were assessed by comparing the averages of measurements taken before and after the treatment. To evaluate the safety of the herbal extract, liver function test and kidney function test results were compared, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (Cr), and estimated glomerular filtration rate (eGFR). Results: The average duration of Oryeong-san consumption was 17.71±26.82 days. Although the FBS decreased and the PP2 slightly increased, these changes were not statistically significant (p>0.05). Safety assessments showed that the average levels of AST decreased, while the level of ALT increased, without statistical significance. The BUN levels also significantly decreased, while Cr and eGFR levels remained stable. Conclusion: This study indicates that Oryeong-san is safe for use in type 2 diabetes patients without significant impact on blood glucose and that it has a positive safety profile.
참고문헌 (26)
- Kahn SE, "Pathophysiology and Treatment of Type 2 Diabetes : Perspectives on the Past, Present, and Future", Lancet, 383(9922), pp.1068~1083 (2014)
- Ma CX, "Cardiovascular disease in type 2diabetes mellitus : progress toward personalized management", Cardiovasc Diabetol, 21(1), pp.74~ (2022)
- American Diabetes Association, "Economic costs of diabetes in the U. S. in 2017", Diabetes Care, 41(5), pp.917~928 (2018)
- UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33)", Lancet, 352(9131), pp.837~853 (1998)
- Hemmingsen B, "Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2diabetes mellitus", Cochrane Database Syst Rev, 11, pp.1465~1858 (2013)
- Loscalzo J, "Harrison's Principles of Internal Medicine" (2022), McGraw Hill
- Di Angelantonio E, "Glycated hemoglobin measurement and prediction of cardiovascular disease", JAMA, 311(12), pp.1225~1233 (2014)
- Han E, "Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes : An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018", Endocrinol Metab, 37(3), pp.466~474 (2022)
- Kim MJ, "Case-series of Nausea and Vomiting Treated with Oryeong-san", Int Korean Med, pp.76~81 (2015)
- 노의준, "古方類聚", pp.242~ (2009), 도서출판 고방
- Lee JY, "Two Cases of Cancer-induced Lymphedema Patients Treated with Oryeongsan", J Korean Orient Intern Med, 34(3), pp.322~328 (2013)
- Jung EH, "Four Cases Report of the Female Lower Urinary Tract Infection with Oryeong-san", J Oriental Obstet Gynecol, 25(4), pp.134~143 (2012)
- Lin E, "Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis-a prospective randomized controlled trial", Afr J Tradit Complement Altern Med, 10(5), pp.199~209 (2013)
- Lin SK, "Traditional Chinese medicine therapy reduces the catheter indwelling risk in dementia patients with difficult voiding symptoms", J Ethnopharmacol, 203, pp.120~126 (2017)
- Jang YJ, "Effect of Oryeongsan on Spontaneously Hypertensive Rat : Decrease of Blood Pressure and Vasodilatory", Herbal Formula Science, 30(3), pp.123~135 (2022)
- Kang JH, "A Case of a Functional Dyspepsia Patient Diagnosed with Water Reversal Syndrome Treated with Oryeong-san", J Int Korean Med, 41(5), pp.806~810 (2020)
- Zuo HL, "Enzyme Activity of Natural Products on Cytochrome P450", Molecules, 27(2), pp.515~ (2022)
- Triplitt C, "Drug Interactions of Medications Commonly Used in Diabetes", Diabetes Spectr, 19(4), pp.202~211 (2006)
- DeFronzo RA, "International Textbook of Diabetes Mellitus", pp.873~1101 (2015), John Wiley & Sons
- American Diabetes Association, "Standards of Medical Care in Diabetes—2021", Diabetes Care, 44(Supplement 1), pp.S1~S232 (2021)
- Kim JH, "Analysis of biological experiment on Oryeong-san(Wuling-san)", J Int Korean Med, 33(1), pp.69~82 (2012)
- The education committee of Korean medicine college for Herbal formula science, "Herbal formula science", pp.504~506 (2003), Yeonglimsa
- Jeong MJ, "An Overview of the Applicability of Oryung-san as an Antihypertensive Agent", J Int Korean Med, 38(4), pp.443~454 (2017)
- Jang IS, "Treatment of Primary Hypertension by Oryung-san Monotherapy : A Case Report", Korean J Orient Intern Med, 35(1), pp.106~110 (2014)
- Jin J, "Insights into Triterpene Acids in Fermented Mycelia of Edible Fungus Poria cocos by a Comparative Study", Molecules, 24(7), pp.1331~ (2019)
- Peng X, "Efficacy and Pharmacological Mechanism of Poria cocos-Based Formulas Combined with Chemotherapy for Ovarian Cancer : A Integrated Systems Pharmacology Study", Front Pharmacol, 13, pp.788810~ (2022)